LEHI, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., a biotechnology company, announced it is exploring the application of its universal cancer vaccine nanoparticle platform for colorectal cancer. This follows recent biodistribution studies suggesting the platform's potential for this new indication.
The company's lead candidate, CVAX, is a nanoparticle-based therapeutic vaccine designed to train the immune system to recognize and attack cancer cells. It is currently in preclinical development, with initial research focused on pancreatic and liver cancers.
According to the company's statement, new findings support the hypothesis that the current nanoparticle design could be adapted for colorectal cancer, one of the most common cancers worldwide. The announcement did not provide specific data or timelines for clinical trials related to this new application.
CancerVax's technology aims to create a broad-spectrum approach to cancer treatment. The exploration into colorectal cancer represents an expansion of its research pipeline, though the platform remains in early-stage development.
